Cogent Biosciences Inc. (COGT)
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
COGT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.23B
- EPS (TTM)
- -$2.16
- Dividend yield
- None
- 52-week range
- 13.78 – 43.73
- Day range
- 29.94 – 30.43
- Volume / Avg
- 1.26M / 1.94M
- Beta
- —
- Shares outstanding
- 173.52M
- Next earnings
- Nov 6, 2026
52-week range
COGT stock today
Shares of Cogent Biosciences (COGT) finished lower on Oct 7 at $30.14, a drop of 0.79% or $0.24 per share, versus the S&P 500's 0.22% decline. Shares are 31.1% below their 52-week high of $43.73, set on Dec 8, 2025 and 118.7% above the 52-week low of $13.78, in the middle of the past year's range. COGT is down 15.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 95.2%.
Cogent Biosciences has posted a net loss over the last twelve months (EPS of -$2.16), so its P/E ratio is not meaningful. Cogent Biosciences's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Cogent Biosciences
Company profileCogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Andrew R. Robbins M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 258
- IPO year
- 2018
- Website
- cogentbio.com
Financial highlights
Full financialsCogent Biosciences reported a net loss of $328.9 million, compared with a loss of $255.9 million a year earlier. Diluted earnings per share came in at -$2.16.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-328.94M | $-255.86M | $-192.41M | $-140.24M | $-72.27M |
| EPS (diluted) | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$55.82+85.20%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $-0.57
- Last reported (Q2 2026)
- Aug 10, 2026
- EPS actual vs est.
- $-0.52 vs —
Cogent Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs COGT |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs COGT |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs COGT |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs COGT |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs COGT |
| LGNDLigand Pharmaceuticals Incorporated | 293.26 | -1.24% | $5.85B | vs COGT |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs COGT |
| RYTMRhythm Pharmaceuticals Inc. | 88.45 | -2.56% | $6.09B | vs COGT |
Indexes, lists and sector
Cogent Biosciences stock FAQ
What is Cogent Biosciences's stock price today?
COGT last traded at $30.14 as of Oct 7, 4:00 PM EDT, down 0.79% on the day. Prices are delayed at least 15 minutes.
Does Cogent Biosciences pay a dividend?
No. Cogent Biosciences does not currently pay a regular cash dividend.
When is Cogent Biosciences's next earnings date?
Cogent Biosciences is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $-0.57.
Who is Cogent Biosciences's CEO?
Mr. Andrew R. Robbins M.B.A. is the chief executive officer of Cogent Biosciences Inc., which has about 258 employees.
Has COGT ever split its stock?
Yes. The most recent COGT stock split was a 1-for-4 split on Nov 9, 2020.
What is the COGT 52-week high?
The 52-week high for COGT is $43.73 and the 52-week low is $13.78. The stock is currently 31.1% below its high.